Evidence mapPaperPMID 37960236Full record

Trial reportNutrients2023

Investigating Nutritional and Inflammatory Status as Predictive Biomarkers in Oligoreccurent Prostate Cancer-A RADIOSA Trial Preliminary Analysis.

Mattia Zaffaroni, Maria Giulia Vincini, Giulia Corrao, Chiara Lorubbio, Ilaria Repetti, Federico Mastroleo, Costantino Putzu, Riccardo Villa, Sofia Netti, Oriana D'Ecclesiis and 7 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03940235 (Radioablation +/- Hormonotherapy for Prostate Cancer Oligorecurrences), which is not on this map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03940235 phase2unknown statusnot on this map

Radioablation +/- Hormonotherapy for Prostate Cancer Oligorecurrences (RADIOSA Trial): Potential of Imaging and Biology

TypeinterventionalSponsorEuropean Institute of OncologyRan2019 to 2024Enrolled150ConditionsOligometastatic Prostate CancerArmsAndrogen deprivation therapy (ADT), SBRT
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Mattia ZaffaroniDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0003-4655-4634
Maria Giulia VinciniDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0001-7830-3149
Giulia CorraoDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-5757-6073
Chiara LorubbioDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Ilaria RepettiDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Federico MastroleoDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0001-6580-6767
Costantino PutzuDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Riccardo VillaDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Sofia NettiDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Oriana D'EcclesiisDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Stefano LuzzagoDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
Francesco Alessandro MistrettaDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.ORCID 0000-0001-5647-4780
Gennaro MusiDepartment of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.
Federica CattaniMedical Physics Unit, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
Sara GandiniDepartment of Experimental Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-1348-4548
Giulia MarvasoDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.ORCID 0000-0002-5339-8038
Barbara Alicja Jereczek-FossaDivision of Radiation Oncology, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy.
University of Milan · ITEuropean Institute of Oncology · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

Italian Association for Cancer Research IG-22159
6 · The paper itself

Abstract

(1) Background: In the RADIOSA phase II randomized clinical trial (NCT03940235), the biology task entails the identification of predictive and prognostic biomarkers in the context of oligorecurrent, castration-sensitive prostate cancer in order to distinguish polymetastatic from oligometastatic disease. This may lay the groundwork for personalized treatments for those patients who could really benefit from metastasis-directed therapies. (2) Methods: Oligorecurrent PCa pts with three or fewer bone or lymph nodal localizations were randomized 1:1 to receive SBRT alone (arm A) or SBRT + 6 months of ADT (arm B). Common serum-derived biomarkers were collected at baseline, and at 3 months after RT. The prognostic nutritional index, an immune and nutrition-based prognostic score, and the controlling nutritional status (CONUT) score, a scoring system for evaluating patient's nutritional status, were calculated in accordance with the body of available literature. As inflammatory indicators, neutrophil-lymphocyte ratio (NLR) and the NLR-albumin ratio (NLRAR) were assessed. Changes in these parameters between baseline and the 3-month timepoint were evaluated both in absolute and relative values. Changes in these parameters between baseline and the 3-month timepoint were evaluated. Significant differences in the trend of these parameters were assessed using the non-parametric Wilcoxon rank-sum test. A network analysis to analyze the relationships between different features stratifying patients according to the arm of study and site of metastases was performed. (3) Results: The current analysis comprised 88 patients (45 arm A, SBRT only, and 43 arm B, SBRT + ADT). When patients were stratified by ADT administration, cholesterol values showed an increasing trend in the group receiving ADT (

Indexed as

Prostatic NeoplasmsBiomarkersBone and BonesHumansLymph NodesMaleNutritional StatusBiomarkersbiomarkersinflammationnutritional statusoligometastatic diseaseprostate cancerquality of life

Identifiers

PMID37960236
PMCPMC10647217
OpenAlexW4388103258

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.